| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5578266 | Journal of Pain and Symptom Management | 2017 | 26 Pages |
Abstract
Neither bevacizumab treatment nor low-grade systemic inflammation as measured by CRP was associated with the increased fatigue levels and raised prevalence of CF, observed during and after BC therapy. Increased fatigue levels at baseline and psychological distress at T3 were associated with CF at T3.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Kristin V. MD, PhD, Olav MD, PhD, Jon H. (Professor), Milada MSc, PhD, Bjørn (Professor), Erik (Professor), Hege MSc, PhD, Elisabeth MSc, Trine (Professor), Cecilie E. MD, PhD,